Ionis Pharmaceuticals continues to attract positive analyst sentiment, with three separate brokerage firms maintaining bullish ratings while trimming their respective price targets. Canaccord Genuity analyst Gary Nachman has maintained a Buy rating on the company, lowering the price target to $95 from $110. Separately, Barclays analyst Eliana Merle has maintained an Overweight rating while reducing the price target from $115 to $90. Additionally, RBC Capital analyst Luca Issi has maintained an Outperform rating, lowering the price target from $100 to $85.

Analyst Ratings and Price Target Summary

Despite the downward revisions in price targets, all three analysts continue to hold constructive views on Ionis Pharmaceuticals' long-term prospects. The following table captures the latest ratings and target adjustments from all three firms:

The concurrent reductions in price targets from Canaccord Genuity, Barclays, and RBC Capital reflect a more conservative near-term valuation approach, even as all firms retain their positive ratings on the stock.

Ionis Pharmaceuticals, Inc. has dosed the first participant in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people living with Dravet syndrome. Dravet syndrome is a rare, severe, and lifelong neurological disorder that typically begins in infancy and is associated with prolonged seizures, developmental delays, cognitive impairments, and an increased risk of sudden death. The advancement of ION337 represents a potential disease-modifying therapy for this condition.

"The first participant to receive ION337 in the ASCEND study marks an important step toward advancing a potential disease modifying therapy for people living with Dravet syndrome," said Holly Kordasiewicz, Ph.D., executive vice president, chief development officer, Ionis. "ION337 is our first wholly owned medicine developed using Ionis’ advanced NMA technology, which is designed to enhance the potency of our medicines and potentially support infrequent intrathecal dosing of every six months or less. This milestone reflects a new wave of scientific innovation across Ionis’ advancing neurology pipeline for people living with serious neurological conditions. We look forward to advancing the development of ION337 alongside the Dravet syndrome community."

The ASCEND study (NCT07531745) is an open-label, Phase 1-2 study evaluating the safety and tolerability of ION337 in children aged 2 to 12 years with a clinical diagnosis of Dravet syndrome. The study consists of two parts: an initial 6-month single ascending dose (SAD) component, followed by a 24-month multiple ascending dose (MAD) component with dosing of ION337 every 6 months, and an additional 7-month safety follow-up period.

ION337 uses next-generation N-Methylacetamide modifications (NMA technology) designed to enhance the potency of splice modulating antisense oligonucleotides (ASOs). This advanced molecular design is intended to provide sustained activity, supporting infrequent dosing. ION337 is designed to increase production of the NaV1.1 protein, which is reduced in people with Dravet syndrome caused by certain SCN1A gene variants. The U.S. Food and Drug Administration (FDA) has granted ION337 Fast Track designation for the treatment of Dravet syndrome.

Study Details